Clinical trials
Relapsed Neuroblastoma clinical trials
Below are recruiting relapsed neuroblastoma clinical trials, each written for real people, not researchers. We’re tracking 21 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05650749Enrolling by invitationPhase 1
GPC2 car T cells for neuroblastoma and retinoblastoma
This trial tests a new treatment using engineered immune cells (CAR T cells) that target a protein called GPC2 found on some cancer cells. It is for patients with high-risk neuroblastoma or metastatic retinoblastoma that has returned or not responded to other treatments.
Philadelphia, PennsylvaniaAges 1 year+ - NCT07211737RecruitingPhase 1
C7R-GD2 CAR-T cells for osteosarcoma or neuroblastoma
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
Houston, TexasAges 1–24 - NCT07027748RecruitingPhase 1
Testing a longer treatment of three drugs for neuroblastoma
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
Boston, MassachusettsAges 1–30 - NCT05400603RecruitingPhase 1
Immunotherapy trial for relapsed neuroblastoma or osteosarcoma
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
Atlanta, GeorgiaAges 1 year+ - NCT06721689RecruitingPhase 1/Phase 2
PEEL-224 with chemo for pediatric solid tumors
This trial tests a new drug called PEEL-224 combined with two chemotherapy medicines (vincristine and temozolomide) for children and young adults with certain solid tumors that have come back or not responded to treatment. It aims to see if this combination is safe and works against the cancer.
Los Angeles, CaliforniaAges 1–30 - NCT07334301RecruitingPhase 1/Phase 2
Combination treatments for relapsed high-risk neuroblastoma
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
SydneyAges 1 year+ - NCT07502287RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for children with neuroblastoma
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
Shenzhen, GuangdongAges 1–21 - NCT06803875RecruitingPhase 1/Phase 2
CAR T cells for relapsed high-risk neuroblastoma
This trial is testing a new type of immunotherapy called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has come back or not responded to standard treatment. The goal is to see if these specially engineered cells can find and destroy the cancer cells.
Boston, MassachusettsAges 1–29 - NCT05562024RecruitingPhase 1
Study drug for B7-H3 positive neuroblastoma after relapse
This Phase 1 study tests TAA06, an injection that targets a marker called B7-H3 on neuroblastoma tumor cells. It is for children who have neuroblastoma that has come back or did not respond to prior treatment, aiming to see whether the treatment is safe and can shrink tumors.
Jinan, ShandongAges 1 year+ - NCT06013618RecruitingPhase 2
Naxitamab for high-risk or relapsed neuroblastoma in children
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
Guangzhou, GuangdongAges 1 year+ - NCT04211675RecruitingPhase 1/Phase 2
Test NK cell infusions with irinotecan, temozolomide, and dinutuximab
This early-phase study tests whether giving donated NK cells with three medicines can shrink neuroblastoma that has come back or not responded well to prior treatment. It’s designed for people who have limited options, and the goal is to see safety and whether the combination works.
Columbus, OhioAges Up to 29 years - NCT07635056RecruitingPhase 2
Natural killer cells for hard-to-treat neuroblastoma
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
Cincinnati, OhioAges 1–39 - NCT04903899RecruitingPhase 2
Lutetium-DOTATATE for relapsed or hard-to-treat neuroblastoma in children
This Phase 2 trial tests a targeted radioactive medicine called 177Lutetium-DOTATATE in children with high-risk neuroblastoma that has returned or did not respond to treatment. It’s designed for tumors that show strong uptake on special scans, which may help the medicine find and treat cancer cells.
Copenhagen, CopenhagenAges 1.5 years+ - NCT07767630RecruitingEarly Phase 1
Targeted radiation therapy for relapsed neuroblastoma
This trial tests a new type of targeted radiation treatment for children and adults with neuroblastoma that has come back or not responded to other treatments. The radiation is attached to a substance that seeks out neuroblastoma cells, aiming to destroy them while limiting harm to healthy tissue.
Chengdu, SichuanAges 1–100 - NCT07085338RecruitingPhase 2
N-803 with chemoimmunotherapy for relapsed neuroblastoma
This trial tests adding a new drug called N-803 to a standard chemo-immunotherapy combination for children and young adults with high-risk neuroblastoma that has come back or not responded to previous treatments. The goal is to see if this combination works better at fighting the cancer.
San Francisco, CaliforniaAges Up to 30 years - NCT06751134RecruitingPhase 1
Engineered immune cells for relapsed neuroblastoma in children
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
Nanjing, JiangsuAges 1–12 - NCT07375563RecruitingPhase 3
Chemoimmunotherapy with NK cells for high-risk neuroblastoma
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
MoscowAges 1.5 years–18 years - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Birmingham, AlabamaAges Up to 30 years - NCT05272371RecruitingPhase 1
Dinutuximab beta plus chemo for childhood neuroblastoma after relapse
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Krakow, MalopolskaAges 1–18 - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT07087002RecruitingPhase 1
GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Palo Alto, CaliforniaAges 1–30
Hear when a new Relapsed Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Relapsed Neuroblastoma trials by city
Studies with a site in or near these metro areas.
Relapsed Neuroblastoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for relapsed neuroblastoma?
- Yes. Clin2 currently lists 21 recruiting relapsed neuroblastoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed neuroblastoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed neuroblastoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.